Vice-Chairman of PhIRDA Drug R&D Specialty Committee, Chairman and CEO of Jacobio Pharmaceuticals
Jacobio Pharmaceuticals Co., Ltd,serving as the Chairman & CEO. Dr. Yinxiang Wang was graduated from the University of Arkansas for Medical Sciences in 1999,and served as a postdoctoral research fellow at the Department of Molecular Biophysics and Biochemistry of Yale University from 1999 to 2003. He returned to China in 2003 and founded Betta Pharmaceuticals,and served as the President and CSO of Betta Pharmaceutiacals,developed Icotinib Hydrochloride (Conmana®),a new molecular entity (NME) for lung cancer. This novel drug is the first small molecule anticancer drug that is completely developed in China and approved by CFDA in 2011.The project won the 1st prize of National Science , the gold medal of WIPO-SIPO Award; Betta formed JV with Amgen (Amgen-Betta Pharmaceuticals) in 2013 and Dr. Wang served as GM. In 2015, he founded Jacobio Pharmaceuticals in Beijing and serving as the Chairman & CEO. Dr. Wang is the second chairman, New Drug R&D Committee of China Pharmaceutical Innovation and Research Development Association (PHIRDA); Associate Chairman, Oncology Drug Clinical Research Committee of Chinese Pharmaceutical Association;Member of Zhongguancun Entrepreneur Advisory Committee.